Mont Vert Group signs $500 M deal to build medical university and hospital in Kazakhstan

IMT News Desk
IMT News Desk
· 2 min read

The private healthcare initiative is being undertaken jointly by SRAM & MRAM Group, Big B Corporation, and KAZIND Medical Group of Kazakhstan

Pune-based leading real estate firm Mont Vert Group has signed a $500 million (approx. Rs 4,300 crore) agreement with Kazakhstan’s Big B Corporation to develop a medical university and a multi-speciality hospital in Kazakhstan.

The announcement was made during the 30th anniversary celebration of SRAM & MRAM Group, held at Raven’s Ait Private Island in London. The event was graced by notable dignitaries including Jayantilal Kaneria, Chairman, Mont Vert Group, Neeraj Kaneria, Managing Director, Mont Vert Group, Ajay Bhandari, Director, Big B Corporation (Kazakhstan), Mahendra Joshi, Director, SRAM & MRAM Group, Nitin Gupta, and Dr Swapnil Kamble, all Directors of SRAM & MRAM Group.

As per a press release by UK-based SRAM & MRAM Group, Mont Vert Group has been entrusted with the construction and development of this project. This private healthcare initiative is being undertaken jointly by SRAM & MRAM Group, Big B Corporation, and KAZIND Medical Group of Kazakhstan.

The deal was made possible due to the efforts of Ajay Bhandari and Mahendra Joshi, Directors of Big B Corporation and SRAM & MRAM Group respectively.

Last October, the Kazakh government approved 243 hectares of land in Astana and 100 hectares in Almaty for the project. The campus will house a medical college accommodating 10,000 students and a multi-speciality hospital with 1,000 beds.

Sailesh Lachu Hiranandani, Chairman, SRAM & MRAM Group, said, “Mont Vert Group represents the pinnacle of excellence in Indian real estate. Their experience and quality commitment make them the ideal partner for this international healthcare venture.”

Read Next

India successfully validates the first indigenous HPV test for Cervical Cancer screening
News
June 13, 2026

India successfully validates the first indigenous HPV test for Cervical Cancer screening

India has achieved a significant milestone in cervical cancer prevention with the successful validation of the country’s first indigenous HPV DNA tests, which meet international standards for cervical cancer screening. Published in the International Journal of Cancer, a multicentre study involving leading Indian and international institutions found that Molbio Diagnostics Truenat HPV-HR Plus met the […]
Article by: IMT News Desk
Glenmark Launches Winlevi® in Key European Markets for the Treatment of Acne Vulgaris
News
June 12, 2026

Glenmark Launches Winlevi® in Key European Markets for the Treatment of Acne Vulgaris

Glenmark Specialty S.A. (GSSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd., has announced the launch of Winlevi® (clascoterone 10 mg/g cream) across key markets in Europe. This follows the grant of marketing authorization of the product for the treatment of acne vulgaris in both adults and adolescents aged 12 to <18 years (with usage in […]
Article by: IMT News Desk
Thyrocare Expands Its Presence in Prayagraj with the Launch of Its New Diagnostic Laboratory
News
June 12, 2026

Thyrocare Expands Its Presence in Prayagraj with the Launch of Its New Diagnostic Laboratory

Thyrocare Technologies Limited has announced the set-up of its new diagnostic laboratory in Prayagraj, Uttar Pradesh, in association with SecondMedic. The new laboratory is equipped with advanced testing infrastructure and supported by trained professionals, enabling timely and error-free diagnostic results. It caters to both specialised and routine testing requirements, offering support to ongoing and preventive […]
Article by: IMT News Desk
AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer
News
June 12, 2026

AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer

AstraZeneca Pharma India Ltd. (AZPIL) announced that the Central Drugs Standard Control Organisation (CDSCO) has approved an additional indication for Trastuzumab Deruxtecan 100 mg/5 mL vial lyophilized powder for concentrate for solution for infusion, in combination with Pertuzumab as a first-line treatment for adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer. In India, HER2-positive breast […]
Article by: IMT News Desk